<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DIHYDROTACHYSTEROL</span><br/>(dye-hye-droe-tak-iss'ter-ole)<br/><span class="topboxtradename">DHT, </span><span class="topboxtradename">DHT Intensol, </span><span class="topboxtradename">Hytakerol<br/></span><b>Classifications:</b> <span class="classification">vitamin d</span>; <span class="classification">regulator, serum calcium</span><br/><b>Pregnancy Category: </b>A<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.125 mg, 0.2 mg, 0.4 mg tablets; 0.2 mg/mL oral solution; 0.125 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Oil-soluble reduction product of ergocalciferol (vitamin D<sub>2</sub>) with pharmacologic actions similar to those of both ergocalciferol and parathyroid hormone. In comparison with ergocalciferol,
         dihydrotachysterol promotes less intestinal absorption of calcium but almost equal phosphate diuresis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acts like parathyroid hormone in ability to raise serum calcium concentrations rapidly; also reported to increase intestinal
         absorption of sodium, potassium, and magnesium.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypocalcemia associated with hypoparathyroidism, both postoperative and idiopathic, and in pseudohypoparathyroidism. Also
         for prophylaxis of hypocalcemic tetany following thyroid surgery.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Vitamin D-resistant rickets (familial hypophosphatemia), osteoporosis, and renal osteodystrophy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sensitivity to vitamin D; hypercalcemia and hypocalcemia associated with renal insufficiency and hyperphosphatemia; renal
         stones, hypervitaminosis D. Safe use during pregnancy (category A), lactation, or in children in amounts exceeding RDA is
         not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypoparathyroidism, Pseudohypoparathyroidism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.752.5 mg/d for several days, then 0.21 mg/d (may need 1.5 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 15 mg/d for 4 d then 0.51.5 mg/d<br/><span class="rdage">Neonate:</span> <span class="rdroute">PO</span> 0.050.1 mg/d<br/><br/><span class="indicationtitle">Thyroidectomy-induced Hypocalcemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.25 mg/d<br/><br/><span class="indicationtitle">Renal Osteodystrophy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.10.6 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.10.5 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Withhold drug if signs and symptoms of hypercalcemia appear (see Appendix F) and report to physician.</li>
<li>Store in tightly closed, light-resistant containers at 15°30° C (59°86° F) unless otherwise
            directed.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, headache, weakness, vertigo, ataxia, atonia, mental depression. <span class="typehead">Endocrine:</span> Hypercalcemia. <span class="typehead">GI:</span> Anorexia, nausea, vomiting, metallic taste, dry mouth, thirst, diarrhea, constipation, abdominal pain. <span class="typehead"> Urogenital:</span>  Nocturia, polyuria, renal calculi. <span class="typehead">Special Senses:</span> Tinnitus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>  Not established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from small intestines. <span class="typehead">Peak:</span> 2 wk. <span class="typehead">Duration:</span> 2 wk. <span class="typehead">Distribution:</span> Distributed in breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolite. <span class="typehead">Elimination:</span> Excreted primarily in bile and feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: serum and urinary calcium levels at least weekly during first month of therapy until they are stabilized, then
            monthly thereafter.
         </li>
<li>Supplement with 1015 g of oral calcium lactate or gluconate daily; adequate calcium intake is necessary for clinical
            response to therapy.
         </li>
<li>Restrict dietary phosphate or administer calcium carbonate supplements with meals, or both, to bind intestinal phosphates
            and improve calcium balance in patients with hyperphosphatemia.
         </li>
<li>Monitor hypoparathyroid patients receiving thiazide diuretics closely; they are prone to develop hypercalcemia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn S&amp;S of hypercalcemia (see Appendix F).</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>